CAMBRIDGE, Mass., March 11, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced that Dr. David Berry, Partner at Flagship Ventures, has been selected by the World Economic Forum as a 2014 Young Global Leader (YGL).
Every year the World Economic Forum acknowledges the most distinguished leaders under the age of 40 who are nominated from around the globe. Dr. Berry is recognized for his professional accomplishments, commitment to society and potential to contribute to shaping the future of the world through his leadership. "I am honored to be recognized among such a distinguished group of leaders and excited to be part of this extraordinary community committed to making a difference in the world," said Dr. Berry.
Dr. Berry's innovations in life sciences and sustainability have led to the founding of many companies including LS9 (selected as a 2008 Technology Pioneer by the World Economic Forum), Joule Unlimited (a 2012 Technology Pioneer), Pronutria, and Seres Health. Currently, Dr. Berry is the CEO of Seres Health, and was the Founding CEO of Pronutria and Joule Unlimited. "At Flagship our dedication to creating, financing, and building breakthrough ventures is consistent with the focus of the Forum of Young Global Leaders to address some of the world's biggest challenges," said Dr. Berry. "Our Flagship VentureLabs companies are founded and built to have the potential to significantly transform their respective industries and truly make an impact on the lives of millions."
"Dr. Berry is a proven innovator and leader whose contributions are a great asset to Flagship and our portfolio companies," said Dr. Noubar Afeyan, Managing Partner and CEO of Flagship Ventures. "We congratulate him on this significant achievement."
More information about the Forum of Young Global Leaders and a complete list of 2014 honorees is available at http://www.weforum.org/community/forum-young-global-leaders.
About Flagship Ventures
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabs™ which invents and launches transformative companies, and Venture Capital, which finances and develops innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team is active in three principal business sectors: therapeutics, health technologies and sustainability. Flagship's portfolio ventures include: Accuri Cytometers (acquired by Becton Dickinson), Adnexus (acquired by Bristol-Myers Squibb), Acceleron (NASDAQ: XLRN), Agios (NASDAQ: AGIO), BIND Therapeutics (NASDAQ: BIND), Concert Pharmaceuticals (NASDAQ: CNCE), Eleven Biotherapeutics (NASDAQ: EBIO), Hypnion (acquired by Eli Lilly), Morphotek (acquired by Eisai), Receptos (NASDAQ: RCPT) and Tetraphase (NASDAQ: TTPH). Additional notable portfolio companies include: Affinnova, Joule Unlimited, and Moderna Therapeutics. For more information, please visit www.flagshipventures.com.
For Flagship Ventures:
SOURCE Flagship Ventures